News (Page 7)

An Open-Label Trial of Granulocyte Macrophage Colony Stimulating Factor Therapy for Moderate Symptomatic Pulmonary Alveolar Proteinosis: Results

Twenty-seven patients with adult idiopathic PAP were screened, and 25 patients were enrolled in the trial. Figure 1 is a flow chart showing the disposition of all screened patients. Circulating anti-GM-CSF antibodies were present in all patients, measured in pretreatment sera as previously described. Among the 25 patients enrolled in the trial, 18 were men…

An Open-Label Trial of Granulocyte Macrophage Colony Stimulating Factor Therapy for Moderate Symptomatic Pulmonary Alveolar Proteinosis: Study Outcomes

The primary end point was an improvement in oxygenation as assessed by a > 10 mm Hg decrease in the room air alveolar-arterial oxygen gradient (P[A-a]O2). For the patients who received GM-CSF therapy after hospital admission for bilateral lavage (history of two or more WLLs in the prior 4 months), the primary outcome variable was…

An Open-Label Trial of Granulocyte Macrophage Colony Stimulating Factor Therapy for Moderate Symptomatic Pulmonary Alveolar Proteinosis: Dosage and Dose Escalation

Patients were treated with recombinant human yeast-derived GM-CSF (Leukine; formerly Immunex Corporation and now Berlex; Seattle, WA) administered subcutaneously once daily for 3 months. Patients were trained to self-administer daily subcutaneous therapy. The starting dose was 250 Mg/d, which was progressively increased to 5 |xg/kg/d for the second month of study, and to 9 |xg/kg/d…

An Open-Label Trial of Granulocyte Macrophage Colony Stimulating Factor Therapy for Moderate Symptomatic Pulmonary Alveolar Proteinosis: Materials and Methods

The study was a prospective, open-label clinical trial of daily GM-CSF therapy in a group of patients with idiopathic PAP. The study was approved by the Institutional Review Board at the Cleveland Clinic Foundation, and informed consent was obtained from all patients prior to enrollment. A diagnosis of idiopathic PAP was confirmed by transbronchial lung…

An Open-Label Trial of Granulocyte Macrophage Colony Stimulating Factor Therapy for Moderate Symptomatic Pulmonary Alveolar Proteinosis

Pulmonary alveolar proteinosis (PAP) is an uncommon idiopathic disease characterized by the deposition of extracellular granular lipoproteina-ceous material within the lung alveoli. To date, < 500 cases have been reported in the literature. There is no specific therapy for PAP. Sequential whole-lung lavage (WLL) is the standard of care.2 WLL is a cumbersome and invasive…

How Authors Can Cope With the Burden of English as an International Language: Take-Home Messages

In order for the revision process to move beyond the simple goal of “fixing” a text to a process in which EIL authors are developing their writing skills on the way toward becoming independent writers, input from both a language professional and an experienced peer is important. The language professional should ideally be a schooled…

How Authors Can Cope With the Burden of English as an International Language: EIL Author Draft

Background: We reviewed the patients who underwent tricuspid valve replacement (TVR) to compare the long-term clinical results of bioprosthetic valve with mechanical valve in tricuspid position. Language Professional Draft Background: The choice of a bioprosthetic vs a mechanical valve in tricuspid valve replacement (TVR) continues to be debated. We reviewed the long-term clinical results of…

Pages: Prev 1 2 3 4 5 6 7 8 ... 34 35 36 Next